Levothyroxine Sodium Tablet Shortage: FDA Reports Discontinuation by Manufacturer

The FDA added levothyroxine sodium tablets (Lannett Company, Inc.) to the Drug Shortages Database on January 14, 2025, citing manufacturer discontinuation. Wholesale drug distributors holding inventory of this product must now manage allocation protocols for a medication taken by approximately 23 million Americans for hypothyroidism and thyroid cancer suppression.

Regulatory Context

The FDA maintains the Drug Shortages Database under Section 506E of the Federal Food, Drug, and Cosmetic Act, as amended by the FDA Safety and Innovation Act (FDASIA) of 2012. Manufacturers must notify FDA at least six months before discontinuing a medically necessary product. The law does not require distributors to report shortages, but wholesale drug distributors operating under state pharmacy board licensure must maintain adequate records of product disposition under 21 CFR Part 205.

When a drug shortage involves a medically necessary product, FDA works with manufacturers to extend expiration dates, expedite regulatory review of competing products, and coordinate with distributors to prevent stockpiling or price gouging. State boards of pharmacy may issue emergency orders regarding allocation, and the Drug Supply Chain Security Act (DSCSA) transaction information requirements remain in effect throughout shortage periods.

Product Details and Timeline

Product Specifications:

• Levothyroxine Sodium Tablets USP
• Manufacturer: Lannett Company, Inc.
• Strengths affected: Multiple (specific strengths listed in FDA database)
• Reason for shortage: Manufacturer discontinuation
• Expected resolution: Discontinued — no restart date

FDA Database Status:

• Current supply: Limited
• Demand level: High (thyroid replacement therapy is lifelong maintenance)
• FDA coordination: Active with remaining manufacturers

Lannett's discontinuation follows its October 2024 announcement of a comprehensive portfolio restructuring. The company cited manufacturing optimization and focus on higher-margin products. The six-month notification period under FDASIA allows FDA and distributors to prepare, but levothyroxine's status as a narrow therapeutic index drug complicates patient switching to alternative manufacturers.

Impact on Wholesale Drug Distribution

Wholesale drug distributors face three immediate operational challenges:

Inventory Management: Distributors with existing Lannett levothyroxine inventory must implement allocation protocols to prevent early depletion. State pharmacy boards may request distribution data to monitor for stockpiling or diversion. Under DSCSA, all transactions must include product identifier, transaction information, and transaction statement regardless of shortage status.

Customer Communication: Chain pharmacies, independent pharmacies, and health systems supplied by affected distributors require notification of supply constraints. Many specialty pharmacies serving endocrinology practices will need to coordinate with prescribers for therapeutic substitution. NDC switches trigger DSCSA verification requirements even when switching between levothyroxine manufacturers.

Alternative Sourcing: Distributors must qualify alternative levothyroxine suppliers to meet customer demand. Remaining manufacturers include Mylan (Viatris), Sandoz, Amneal, and brand product Synthroid (AbbVie). Each requires verification of FDA registration status, state wholesale drug distributor licensure, and NABP accreditation where applicable. Authorization for gray market purchases from secondary wholesalers increases compliance risk during shortage periods.

The FDA's drug shortage management guidance recommends against distributors implementing first-come-first-served allocation during critical shortages. Instead, allocation should be based on historical purchasing patterns to prevent hoarding and ensure equitable distribution across patient populations. State boards may audit distribution records post-shortage to verify compliance.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold verified FDA registration — a baseline requirement for distributing prescription drugs in interstate commerce. During drug shortage periods, procurement teams often expand their distributor network beyond established trading partners, increasing the compliance verification workload.

The directory's average compliance score of 51/100 reflects a "Fair" tier, indicating that most tracked entities maintain basic licensure but lack comprehensive verification signals like NABP accreditation. Only 63 entities (5%) hold NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation — formerly the gold standard for distributor verification. This limited accreditation rate means QA managers cannot rely solely on NABP status when qualifying alternative levothyroxine suppliers during this shortage.

73 entities in the directory have at least one FDA enforcement action on record (recalls, warning letters, or import alerts). During drug shortage management, the pressure to source from unfamiliar distributors increases the risk of engaging non-compliant entities. Cross-referencing potential suppliers against enforcement history is standard due diligence.

Compliance Actions for QA and Procurement Teams

Verify alternative supplier credentials before purchase orders:

• Use the ColdChainCheck directory to check FDA registration status, state licensure coverage, and enforcement history for any new levothyroxine distributor
• Require DSCSA-compliant transaction documentation (TI/TH/TS) regardless of shortage urgency — shortcuts during shortages create audit exposure
• Document the reason for supplier changes in quality system records; auditors will ask why you deviated from approved vendor lists

Monitor remaining levothyroxine manufacturers:

• FDA's Drug Shortages Database lists current supply status for each remaining manufacturer
• If additional manufacturers report shortages, distributors may face allocation from multiple suppliers simultaneously
• ColdChainCheck tracks recalls by product and manufacturer; use this to assess quality history of alternative sources

Review allocation protocols with legal counsel:

• State pharmacy boards may issue emergency allocation orders during critical shortages
• Historical purchasing data should drive allocation decisions, not customer pressure
• Document allocation methodology before implementing — post-shortage audits focus on equitable distribution

Update trading partner verification records:

• DSCSA requires annual verification of trading partners; shortage-related supplier additions trigger re-verification
• State wholesale drug distributor licenses must cover the ship-to jurisdiction; check multi-state coverage in the directory

ColdChainCheck's compliance guides cover DSCSA transaction requirements, state licensure verification, and FDA enforcement signal interpretation. The directory updates weekly as new license data and enforcement actions are published by state boards and FDA.

Disclaimer: This article provides informational content based on publicly available regulatory data and is not legal or compliance advice. Consult with qualified legal counsel and regulatory affairs professionals regarding specific drug shortage management obligations.